Barclays PLC Janux Therapeutics, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 15,500 shares of JANX stock, worth $649,295. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,500
Previous 47,722
67.52%
Holding current value
$649,295
Previous $511,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding JANX
# of Institutions
123Shares Held
25.3MCall Options Held
92KPut Options Held
161K-
Orbimed Advisors LLC San Diego, CA4.28MShares$179 Million3.62% of portfolio
-
Bvf Inc San Francisco, CA2.92MShares$122 Million3.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$116 Million0.2% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.35MShares$98.5 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.97MShares$82.3 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.75B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...